Interferon Beta News Today

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.

Damaged mitochondrial DNA initiates and spreads Parkinsons disease pathology, potentially opening new avenues for early diagnosis, researchers say.

/PRNewswire/ -- Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced today that it has reshaped the...

Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including

EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut...

This report gives an insight into the global Interferon market and predicts the future growth prospects and the trends that may exhibit in the market...

Global Multiple Sclerosis Treatment Market Size, Study, By Product, Application, And Forecasts 2023-2031 Bharat Book Bureau Provides the Trending…

Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.

Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say thats both a blessing and problem.